Molecular Profiling Now Guides Every Major CRC Treatment Decision

A veteran sits across from his or her VA oncologist with a new diagnosis of metastatic colorectal cancer. Ten years ago, the conversation followed a well-traveled path: Treatment included a chemotherapy doublet, maybe with a biologic. CRC was no less molecularly complex, but fewer biomarkers had been identified or targeted.

The CRC Map Is Complete. How to Use It?

In the mapping of colorectal cancer for much of the past three decades the dominant question has been “which molecular features of this tumor matter?” Now, the question shifts to “how can veterans benefit?”

What Matters in Survival, Treatment of Lymphoid Cancers?

Oncologists balance the most effective treatment against the likelihood of adverse effects for every patient with cancer. Generally, the assumption is that older patients and those with more comorbidities and poorer performance status will experience more negative effects, including potentially fatal toxicity, from aggressive treatment. A study presented at the American Society of Clinical Oncology annual meeting in June calls into question this assumption for at least some patients and specific malignancies.

Choosing the Right Regimen for Elderly Patients with Advanced RCC

Most clinical trials provide limited guidance on the appropriate treatment of patients seen in clinical practice. Particularly in oncology, participants in trials tend to be significantly younger and in substantially better health than the average patient. Renal cell carcinoma (RCC) provides a clear example of the challenge.